Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:ZBIO

Zenas BioPharma Q3 2025 Earnings Report

Zenas BioPharma logo
$28.74 -0.69 (-2.34%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$28.67 -0.07 (-0.23%)
As of 07/10/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Zenas BioPharma EPS Results

Actual EPS
-$1.22
Consensus EPS
-$0.87
Beat/Miss
Missed by -$0.35
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$10.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q3 2025
Date
11/12/2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zenas BioPharma's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Zenas BioPharma's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Zenas BioPharma's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Zenas BioPharma Earnings Headlines

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zenas-biopharma-zbio-best-ipo-135853785.html
Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Price Target at $44.29
July 9 at 3:33 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30888089
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
July 11 at 1:00 AM  |  Reagan Gold Group (Ad)
Zenas BioPharma Inc ZBIO
June 27, 2026  |  morningstar.comM
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZBIO/pressreleases/36903055/zenas-biopharma-announces-positive-phase-3-obexelimab-results/
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
June 21, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/21/zenas-biopharma-s-ceo-purchased-60-000-company-shares-here-s-a-deeper-look-at-the-transaction/
See More Zenas BioPharma Headlines

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

View Zenas BioPharma Profile
Earnings Tools